A derivative of imidazobenzimidazole, ML106, inhibits melanin synthesis via p38 MAPK activation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Su Yeon | - |
dc.contributor.author | Lee, Seung Hoon | - |
dc.contributor.author | Shin, Jun Seob | - |
dc.contributor.author | Lee, Doohyun | - |
dc.contributor.author | Lee, Taeho | - |
dc.contributor.author | Park, Kyoung-Chan | - |
dc.contributor.author | Min, Kyung Hoon | - |
dc.contributor.author | Kim, Dong-Seok | - |
dc.date.available | 2019-03-08T21:58:44Z | - |
dc.date.issued | 2014-05 | - |
dc.identifier.issn | 0031-7144 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/12265 | - |
dc.description.abstract | We investigated the effects of ML106 on melanogenesis in B16F10 melanoma cells. Our results showed that ML106 decreased melanin content and tyrosinase activity in a dose-dependent manner. Interestingly, ML106 did not inhibit microphthalmia-associated transcription factor (MITF) expression, but did decrease tyrosinase expression. Thus, we further investigated the expression and degradation of tyrosinase and related signal transduction pathways. Although ML106 increased glycogen synthase kinase 3 beta (GSK3 beta) activation, the level of beta-catenin level was not affected. Thus, we excluded the involvement of GSK3 beta and beta-catenin in ML106-induced hypopigmentation. However, ML106 induced the phosphorylation of p38 mitogen-activated protein kinase (MAPK), causing down-regulation of tyrosinase. Thus, we next investigated whether tyrosinase down-regulation was due to proteasomal degradation by p38 MAPK activation. We found that ML106-induced tyrosinase down-regulation was restored by MG132, a proteasome inhibitor. Thus, we propose that ML106 has hypopigmentary activity through tyrosinase degradation via p38 MAPK phosphorylation. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | GOVI-VERLAG PHARMAZEUTISCHER VERLAG GMBH | - |
dc.title | A derivative of imidazobenzimidazole, ML106, inhibits melanin synthesis via p38 MAPK activation | - |
dc.type | Article | - |
dc.identifier.doi | 10.1691/ph.2014.3868 | - |
dc.identifier.bibliographicCitation | PHARMAZIE, v.69, no.5, pp 353 - 357 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000335715300006 | - |
dc.identifier.scopusid | 2-s2.0-84900539520 | - |
dc.citation.endPage | 357 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 353 | - |
dc.citation.title | PHARMAZIE | - |
dc.citation.volume | 69 | - |
dc.type.docType | Article | - |
dc.publisher.location | 독일 | - |
dc.subject.keywordPlus | UBIQUITIN-PROTEASOME PATHWAY | - |
dc.subject.keywordPlus | SKIN PIGMENTATION | - |
dc.subject.keywordPlus | PROTEIN-KINASE | - |
dc.subject.keywordPlus | SIGNALING PATHWAYS | - |
dc.subject.keywordPlus | B16 CELLS | - |
dc.subject.keywordPlus | TYROSINASE | - |
dc.subject.keywordPlus | MELANOGENESIS | - |
dc.subject.keywordPlus | DEGRADATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MATURATION | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.